| 1 |
18281615 | 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines. | 2008 Jun |
4 |
| 2 |
18375819 | BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. | 2008 Apr |
1 |
| 3 |
18676857 | Oxidative stress plays a critical role in inactivating mutant BRAF by geldanamycin derivatives. | 2008 Aug 1 |
1 |
| 4 |
16371460 | V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. | 2006 Jan 3 |
1 |
| 5 |
16322212 | Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. | 2005 Dec 1 |
1 |